? Prostate cancer is the most common malignancy of men in the U.S. and there is an urgent need to develop signatures that distinguish clinically significant disease with life threatening potential from the more common """"""""indolent disease"""""""". We have developed methods for determining cell-specific gene expression of prostate carcinoma for four major cell types or groups within prostate carcinoma, including tumor cells, BPH, stroma, and cystic atrophy, and have identified over 3900 genes that are uniformly expressed in one cell type or another. The approach has been extended to identify ~1100 genes specifically associated with relapse as a surrogate for aggressive prostate cancer. These genes are lists by bioinformatics (Aim 1) and experimental methods (Aims 2-4) to develop a predictive signature and to validate the signature in a prospective trial. A consortium of strategic partners will cooperate in completing this goal. We will work with Jeffrey Trent of TGen to analyze 100 fresh surgical samples by quantitative PCR for 200 prioritized genes (Aim 2). Strategic partners at the University of California at San Diego and at Irvine will supplement the SKCC/Sharp HealthCare collection of clinically annotated paraffin blocks of prostate cancer to complete a current project to make a 1000 case tissue microarray (TMA). This TMA will be examined with 200 prioritized antibodies, manufactured by a commercial strategic partner, in cooperation with John Reed of the Burnham Institute (Aim 3). These arrays are specifically designed to (i) correlate gene expression with survival in a retrospective study, (ii) test whether stroma specific genes are correlated with adverse clinical outcomes, and (iii) whether tissue removed prior to the development of prostate cancer expresses predictive genes. Genes that are successfully validated by these methods will be utilized in a prospective observational clinical trial to be carried out at three sites (the Northwestern University Medical School Prostate SPORE, UCSD, and SKCC/Sharp HealthCare) to test the ability of the signatures to accurately predict early relapse (Aim 4). Changes in genes that are predictive of clinically relevant events will have strong justification for further development as predictive biomarkers. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA114810-02
Application #
7127663
Study Section
Special Emphasis Panel (ZCA1-SRRB-4 (J1))
Program Officer
Jacobson, James W
Project Start
2005-09-30
Project End
2010-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
2
Fiscal Year
2006
Total Cost
$1,742,858
Indirect Cost
Name
University of California Irvine
Department
Pathology
Type
Schools of Medicine
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
Zhu, Jianguo; Pan, Cong; Jiang, Jun et al. (2015) Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China. Oncotarget 6:16757-65
Chen, Xin; McClelland, Michael; Jia, Zhenyu et al. (2015) The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression differences in tumor-adjacent stroma. Oncotarget 6:1865-73
Rahmatpanah, Farah B; Jia, Zhenyu; Chen, Xin et al. (2015) A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors. Oncotarget 6:1286-301
Cheng, Chunmei; Pal, Sukumar; Tifrea, Delia et al. (2014) A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect 16:244-52
Lee, Chung; Jia, Zhenyu; Rahmatpanah, Farah et al. (2014) Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-? and IGF signaling. Biomed Res Int 2014:502093
Zhang, Qiang; Yu, Nengwang; Lee, Chung (2014) Mysteries of TGF-? Paradox in Benign and Malignant Cells. Front Oncol 4:94
Correa, Ricardo G; Krajewska, Maryla; Ware, Carl F et al. (2014) The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling. Oncotarget 5:1666-82
Lee, Chung; Zhang, Qiang; Kozlowski, James et al. (2013) Natural products and transforming growth factor-beta (TGF-?) signaling in cancer development and progression. Curr Cancer Drug Targets 13:500-5
Jia, Zhenyu; Wang, Yipeng; Hu, Yuanjie et al. (2013) A sample selection strategy to boost the statistical power of signature detection in cancer expression profile studies. Anticancer Agents Med Chem 13:203-11
An, Yi; Kiang, Alan; Lopez, Jay Patrick et al. (2012) Cigarette smoke promotes drug resistance and expansion of cancer stem cell-like side population. PLoS One 7:e47919

Showing the most recent 10 out of 34 publications